Lundbeck and Otuska’s brexpiprazole hits the mark in PTSD trial

Lundbeck and Otuska’s brexpiprazole-sertraline cocktail has hit the mark in a post-traumatic stress disorder phase 2. The data give Lundbeck a boost at a time when its recently installed CEO is hunting for ways to improve on lackluster growth forecasts.